Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialW. Timothy Garvey, Anuj Bhargava, Naveed Sattar et al.|The Lancet|2023Cited by 676
Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 DiabetesDaniel Edmonston, Neha J. Pagidipati, Elizabeth Lydon et al.|JAMA Network Open|2024Cited by 27